Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Patient burden associated with acute & chronic resistant infections
Inspiring stakeholders to take action on antimicrobial resistance (AMR) starts with communicating the current and future burden of...